SC

Strategy Canon

Certara: sourced choices

36 product and go-to-market choices, oldest first. Back to the case study

  1. 1996Product · Research code Geoff Tucker and Amin Rostami-Hodjegan wrote FORTRAN programs to assess drug metabolism in human populations before any product existed. CT32
  2. 1999Product · Windows simulator From 1999 the algorithms were built into a Windows simulator usable without programming. CT32
  3. 1999Go_To_Market · Consortium Simcyp organized development through a consortium of drug companies, which Rostami-Hodjegan said he inaugurated with the business in 1999. CT3
  4. 2005-05Product · WinNonlin Pharsight sold WinNonlin as a desktop subscription at about $5,000, alongside an enterprise data server and trial simulator. CT17
  5. 2005-05Go_To_Market · Consulting with software Pharsight sold consulting alongside software ($12.1 million software, $10.5 million consulting in fiscal 2005). CT17
  6. 2005-10Go_To_Market · Member terms Consortium members licensed the software and consultancy while contributing to their development. CT30
  7. 2005-10Go_To_Market · Regulators and academics Regulatory bodies and universities took part in the consortium alongside companies. CT30
  8. 2006Product · Virtual populations The simulator was built around virtual populations with demographic, genetic and environmental variability. CT31
  9. 2006Product · Paediatric simulator Simcyp added a paediatric simulator. CT32
  10. 2006Go_To_Market · Workshops Simcyp ran training workshops on predicting in vivo behavior from laboratory data. CT31
  11. 2008-04Go_To_Market · Member breadth Nine of the top ten drug companies were consortium members by 2008; Pfizer and AstraZeneca renewed and Takeda and Sanofi-Aventis joined in 2005. CT54
  12. 2008-04-03Product · Version 8 Version 8 added formulation-aware absorption, disease populations such as cirrhosis, renal impairment and obesity, and a Japanese population. CT54
  13. 2008-09Product · Combined tools Tripos combined its SYBYL molecular design tools with Pharsight's pharmacokinetic tools. CT15
  14. 2008-09Go_To_Market · Pharsight purchase Tripos, recapitalized by Vector Capital, acquired Pharsight to form Certara. CT15
  15. 2009-06-29Product · Phoenix platform Pharsight relaunched WinNonlin as Phoenix WinNonlin 6.0, backward compatible with earlier versions. CT16
  16. 2010-01Go_To_Market · FDA collaboration Pharsight worked with the FDA under a cooperative agreement and supplied the agency with Phoenix tools. CT18
  17. 2010-01-08Product · FDA CRADA tools Phoenix NLME and Phoenix Connect were built under a cooperative agreement with the FDA; Connect worked with SAS, R and NONMEM. CT18
  18. 2012-02Go_To_Market · Academic licences Simcyp offered not-for-profit academic licences, kept after the sale. CT6
  19. 2012-02-28Go_To_Market · Simcyp purchase Certara acquired Simcyp for $32 million. CT6
  20. 2013Product · Scope growth Simcyp started with static drug-interaction calculations and expanded to dynamic models and full physiologically based pharmacokinetic (PBPK) modeling. CT2
  21. 2013Product · Quality system Simcyp built a data-management and QA system for validation and automated testing, described as important to regulators. CT2
  22. 2013Product · Maintenance effort Simcyp put more than 40 person-years of effort a year into updates. CT2
  23. 2014-04-15Go_To_Market · Regulatory writing Certara acquired Synchrogenix, a regulatory writing firm, its first large services acquisition. CT39
  24. 2017-07-11Go_To_Market · EQT buyout EQT bought Certara from Arsenal at an $850 million enterprise value. CT40
  25. 2020-02Go_To_Market · Roadmap voting Members voted each year on features, producing a prioritized wish list for each release. CT48
  26. 2020-10-01Go_To_Market · Regulator licences The FDA held more than 400 licences to Certara software across its divisions. CT38
  27. 2020-12-11Go_To_Market · IPO Certara listed on Nasdaq at $23 a share. CT35
  28. 2021-03Go_To_Market · Cross-selling More than 90% of the top 50 customers bought both biosimulation and regulatory or market-access work. CT25
  29. 2021-08-05Product · Pinnacle 21 Certara acquired Pinnacle 21, clinical-data validation software used by the FDA and Japan's PMDA. CT21
  30. 2021-08-05Go_To_Market · Pinnacle 21 price Certara paid $310 million for Pinnacle 21 in cash and stock. CT21
  31. 2024Product · CoAuthor Certara offered CoAuthor software for generating regulatory documents. CT23
  32. 2024-07-09Product · Discovery software Certara acquired Chemaxon to add discovery cheminformatics, after adding QSP software in 2023. CT22
  33. 2025-08-04Product · EMA qualification Simcyp received an EMA qualification opinion for three drug-interaction contexts of use. CT37
  34. 2025-12-11Go_To_Market · New CEO Certara named Jon Resnick, from IQVIA, CEO from January 2026. CT19
  35. 2026-04-22Go_To_Market · Services divestiture Certara agreed to sell its regulatory and medical writing business, about $50 million of revenue, to Veristat for up to $135 million. CT11
  36. 2026-08Go_To_Market · Restructuring Certara cut its workforce 5% and described a shift toward software, now 53% of revenue. CT50